nodes	percent_of_prediction	percent_of_DWPC	metapath
Fentanyl—CYP3A7—Delavirdine—acquired immunodeficiency syndrome	0.0371	0.0523	CbGbCtD
Fentanyl—CYP3A7-CYP3A51P—Delavirdine—acquired immunodeficiency syndrome	0.0371	0.0523	CbGbCtD
Fentanyl—CYP3A7-CYP3A51P—Indinavir—acquired immunodeficiency syndrome	0.032	0.0451	CbGbCtD
Fentanyl—CYP3A7—Indinavir—acquired immunodeficiency syndrome	0.032	0.0451	CbGbCtD
Fentanyl—CYP3A7—Nelfinavir—acquired immunodeficiency syndrome	0.0311	0.0438	CbGbCtD
Fentanyl—CYP3A7-CYP3A51P—Nelfinavir—acquired immunodeficiency syndrome	0.0311	0.0438	CbGbCtD
Fentanyl—CYP3A5—Nevirapine—acquired immunodeficiency syndrome	0.0308	0.0433	CbGbCtD
Fentanyl—CYP3A7—Saquinavir—acquired immunodeficiency syndrome	0.0281	0.0396	CbGbCtD
Fentanyl—CYP3A7—Ritonavir—acquired immunodeficiency syndrome	0.0281	0.0396	CbGbCtD
Fentanyl—CYP3A7-CYP3A51P—Saquinavir—acquired immunodeficiency syndrome	0.0281	0.0396	CbGbCtD
Fentanyl—CYP3A7-CYP3A51P—Ritonavir—acquired immunodeficiency syndrome	0.0281	0.0396	CbGbCtD
Fentanyl—CYP3A5—Delavirdine—acquired immunodeficiency syndrome	0.0278	0.0392	CbGbCtD
Fentanyl—CYP3A5—Amprenavir—acquired immunodeficiency syndrome	0.0278	0.0392	CbGbCtD
Fentanyl—CYP3A5—Indinavir—acquired immunodeficiency syndrome	0.024	0.0338	CbGbCtD
Fentanyl—CYP3A5—Nelfinavir—acquired immunodeficiency syndrome	0.0233	0.0329	CbGbCtD
Fentanyl—CYP3A5—Ritonavir—acquired immunodeficiency syndrome	0.0211	0.0297	CbGbCtD
Fentanyl—CYP3A5—Saquinavir—acquired immunodeficiency syndrome	0.0211	0.0297	CbGbCtD
Fentanyl—ABCB1—Lopinavir—acquired immunodeficiency syndrome	0.02	0.0282	CbGbCtD
Fentanyl—ABCB1—Amprenavir—acquired immunodeficiency syndrome	0.0181	0.0255	CbGbCtD
Fentanyl—ABCB1—Indinavir—acquired immunodeficiency syndrome	0.0156	0.022	CbGbCtD
Fentanyl—ABCB1—Nelfinavir—acquired immunodeficiency syndrome	0.0152	0.0214	CbGbCtD
Fentanyl—ABCB1—Ritonavir—acquired immunodeficiency syndrome	0.0137	0.0193	CbGbCtD
Fentanyl—ABCB1—Saquinavir—acquired immunodeficiency syndrome	0.0137	0.0193	CbGbCtD
Fentanyl—ABCB1—Zidovudine—acquired immunodeficiency syndrome	0.0132	0.0185	CbGbCtD
Fentanyl—CYP3A4—Efavirenz—acquired immunodeficiency syndrome	0.0128	0.018	CbGbCtD
Fentanyl—CYP3A4—Lopinavir—acquired immunodeficiency syndrome	0.012	0.0169	CbGbCtD
Fentanyl—CYP3A4—Nevirapine—acquired immunodeficiency syndrome	0.012	0.0169	CbGbCtD
Fentanyl—CYP3A4—Delavirdine—acquired immunodeficiency syndrome	0.0108	0.0153	CbGbCtD
Fentanyl—CYP3A4—Amprenavir—acquired immunodeficiency syndrome	0.0108	0.0153	CbGbCtD
Fentanyl—ABCB1—Lamivudine—acquired immunodeficiency syndrome	0.0102	0.0143	CbGbCtD
Fentanyl—CYP3A4—Indinavir—acquired immunodeficiency syndrome	0.00936	0.0132	CbGbCtD
Fentanyl—CYP3A4—Nelfinavir—acquired immunodeficiency syndrome	0.00909	0.0128	CbGbCtD
Fentanyl—CYP3A4—Ritonavir—acquired immunodeficiency syndrome	0.00822	0.0116	CbGbCtD
Fentanyl—CYP3A4—Saquinavir—acquired immunodeficiency syndrome	0.00822	0.0116	CbGbCtD
Fentanyl—CYP3A4—Zidovudine—acquired immunodeficiency syndrome	0.00788	0.0111	CbGbCtD
Fentanyl—OPRM1—nerve—acquired immunodeficiency syndrome	0.00148	0.148	CbGeAlD
Fentanyl—OPRD1—Peptide GPCRs—ACKR1—acquired immunodeficiency syndrome	0.000652	0.0276	CbGpPWpGaD
Fentanyl—CYP3A5—blood plasma—acquired immunodeficiency syndrome	0.000609	0.0609	CbGeAlD
Fentanyl—OPRK1—Peptide GPCRs—ACKR1—acquired immunodeficiency syndrome	0.000572	0.0242	CbGpPWpGaD
Fentanyl—OPRD1—Peptide ligand-binding receptors—CCL3L1—acquired immunodeficiency syndrome	0.000506	0.0214	CbGpPWpGaD
Fentanyl—OPRD1—nervous system—acquired immunodeficiency syndrome	0.000489	0.049	CbGeAlD
Fentanyl—OPRM1—Peptide GPCRs—ACKR1—acquired immunodeficiency syndrome	0.000483	0.0204	CbGpPWpGaD
Fentanyl—OPRD1—central nervous system—acquired immunodeficiency syndrome	0.000471	0.0471	CbGeAlD
Fentanyl—OPRK1—nervous system—acquired immunodeficiency syndrome	0.000469	0.0469	CbGeAlD
Fentanyl—CYP3A4—blood plasma—acquired immunodeficiency syndrome	0.000457	0.0457	CbGeAlD
Fentanyl—OPRK1—central nervous system—acquired immunodeficiency syndrome	0.000452	0.0452	CbGeAlD
Fentanyl—OPRK1—Peptide ligand-binding receptors—CCL3L1—acquired immunodeficiency syndrome	0.000444	0.0188	CbGpPWpGaD
Fentanyl—OPRM1—blood—acquired immunodeficiency syndrome	0.000411	0.0411	CbGeAlD
Fentanyl—OPRM1—spinal cord—acquired immunodeficiency syndrome	0.000396	0.0396	CbGeAlD
Fentanyl—OPRM1—Peptide ligand-binding receptors—CCL3L1—acquired immunodeficiency syndrome	0.000375	0.0159	CbGpPWpGaD
Fentanyl—OPRD1—brain—acquired immunodeficiency syndrome	0.000374	0.0374	CbGeAlD
Fentanyl—OPRD1—Peptide GPCRs—CCR2—acquired immunodeficiency syndrome	0.000364	0.0154	CbGpPWpGaD
Fentanyl—OPRK1—brain—acquired immunodeficiency syndrome	0.000359	0.0359	CbGeAlD
Fentanyl—OPRD1—Peptide GPCRs—CXCR4—acquired immunodeficiency syndrome	0.000342	0.0145	CbGpPWpGaD
Fentanyl—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	0.000339	0.0144	CbGpPWpGaD
Fentanyl—OPRM1—nervous system—acquired immunodeficiency syndrome	0.000334	0.0334	CbGeAlD
Fentanyl—ABCB1—blood plasma—acquired immunodeficiency syndrome	0.000324	0.0324	CbGeAlD
Fentanyl—OPRM1—central nervous system—acquired immunodeficiency syndrome	0.000321	0.0321	CbGeAlD
Fentanyl—OPRK1—Peptide GPCRs—CCR2—acquired immunodeficiency syndrome	0.000319	0.0135	CbGpPWpGaD
Fentanyl—OPRD1—Peptide ligand-binding receptors—ACKR1—acquired immunodeficiency syndrome	0.000307	0.013	CbGpPWpGaD
Fentanyl—OPRK1—Peptide GPCRs—CXCR4—acquired immunodeficiency syndrome	0.0003	0.0127	CbGpPWpGaD
Fentanyl—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	0.000298	0.0126	CbGpPWpGaD
Fentanyl—OPRD1—Peptide ligand-binding receptors—CCL4—acquired immunodeficiency syndrome	0.000277	0.0117	CbGpPWpGaD
Fentanyl—OPRM1—Peptide GPCRs—CCR2—acquired immunodeficiency syndrome	0.00027	0.0114	CbGpPWpGaD
Fentanyl—OPRK1—Peptide ligand-binding receptors—ACKR1—acquired immunodeficiency syndrome	0.000269	0.0114	CbGpPWpGaD
Fentanyl—OPRD1—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	0.000258	0.0109	CbGpPWpGaD
Fentanyl—OPRM1—brain—acquired immunodeficiency syndrome	0.000255	0.0255	CbGeAlD
Fentanyl—OPRM1—Peptide GPCRs—CXCR4—acquired immunodeficiency syndrome	0.000254	0.0107	CbGpPWpGaD
Fentanyl—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	0.000252	0.0106	CbGpPWpGaD
Fentanyl—OPRK1—Peptide ligand-binding receptors—CCL4—acquired immunodeficiency syndrome	0.000243	0.0103	CbGpPWpGaD
Fentanyl—OPRD1—Peptide GPCRs—CCR5—acquired immunodeficiency syndrome	0.000235	0.00993	CbGpPWpGaD
Fentanyl—CYP3A5—digestive system—acquired immunodeficiency syndrome	0.000234	0.0234	CbGeAlD
Fentanyl—OPRM1—Peptide ligand-binding receptors—ACKR1—acquired immunodeficiency syndrome	0.000227	0.00961	CbGpPWpGaD
Fentanyl—OPRK1—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	0.000227	0.00959	CbGpPWpGaD
Fentanyl—CYP3A5—blood—acquired immunodeficiency syndrome	0.000223	0.0223	CbGeAlD
Fentanyl—OPRM1—IL4-mediated signaling events—IL10—acquired immunodeficiency syndrome	0.000222	0.00937	CbGpPWpGaD
Fentanyl—OPRM1—IL4-mediated signaling events—CD40LG—acquired immunodeficiency syndrome	0.000222	0.00937	CbGpPWpGaD
Fentanyl—OPRM1—IL4-mediated signaling events—IL4—acquired immunodeficiency syndrome	0.000216	0.00912	CbGpPWpGaD
Fentanyl—CYP3A5—vagina—acquired immunodeficiency syndrome	0.000207	0.0207	CbGeAlD
Fentanyl—OPRK1—Peptide GPCRs—CCR5—acquired immunodeficiency syndrome	0.000206	0.0087	CbGpPWpGaD
Fentanyl—OPRD1—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	0.000206	0.0087	CbGpPWpGaD
Fentanyl—OPRM1—Peptide ligand-binding receptors—CCL4—acquired immunodeficiency syndrome	0.000205	0.00869	CbGpPWpGaD
Fentanyl—CYP3A5—lung—acquired immunodeficiency syndrome	0.000196	0.0196	CbGeAlD
Fentanyl—OPRM1—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	0.000192	0.0081	CbGpPWpGaD
Fentanyl—OPRD1—Peptide ligand-binding receptors—CCL3—acquired immunodeficiency syndrome	0.000189	0.00801	CbGpPWpGaD
Fentanyl—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.000186	0.00787	CbGpPWpGaD
Fentanyl—OPRK1—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	0.00018	0.00763	CbGpPWpGaD
Fentanyl—ABCB1—retina—acquired immunodeficiency syndrome	0.000177	0.0177	CbGeAlD
Fentanyl—CYP3A4—digestive system—acquired immunodeficiency syndrome	0.000176	0.0176	CbGeAlD
Fentanyl—OPRM1—Peptide GPCRs—CCR5—acquired immunodeficiency syndrome	0.000174	0.00736	CbGpPWpGaD
Fentanyl—OPRD1—Peptide ligand-binding receptors—CCR2—acquired immunodeficiency syndrome	0.000171	0.00725	CbGpPWpGaD
Fentanyl—CYP3A4—blood—acquired immunodeficiency syndrome	0.000167	0.0168	CbGeAlD
Fentanyl—OPRK1—Peptide ligand-binding receptors—CCL3—acquired immunodeficiency syndrome	0.000166	0.00702	CbGpPWpGaD
Fentanyl—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.000163	0.0069	CbGpPWpGaD
Fentanyl—OPRM1—TCR Signaling Pathway—CD8A—acquired immunodeficiency syndrome	0.000163	0.00688	CbGpPWpGaD
Fentanyl—OPRD1—Peptide ligand-binding receptors—CXCL12—acquired immunodeficiency syndrome	0.000161	0.00681	CbGpPWpGaD
Fentanyl—OPRD1—Peptide ligand-binding receptors—CXCR4—acquired immunodeficiency syndrome	0.000161	0.00681	CbGpPWpGaD
Fentanyl—OPRD1—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.000157	0.00662	CbGpPWpGaD
Fentanyl—OPRM1—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	0.000152	0.00645	CbGpPWpGaD
Fentanyl—OPRK1—Peptide ligand-binding receptors—CCR2—acquired immunodeficiency syndrome	0.00015	0.00635	CbGpPWpGaD
Fentanyl—OPRM1—TCR Signaling Pathway—CCR5—acquired immunodeficiency syndrome	0.000149	0.00629	CbGpPWpGaD
Fentanyl—OPRD1—G alpha (i) signalling events—CCR2—acquired immunodeficiency syndrome	0.000144	0.00611	CbGpPWpGaD
Fentanyl—OPRD1—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.000142	0.00599	CbGpPWpGaD
Fentanyl—OPRK1—Peptide ligand-binding receptors—CXCR4—acquired immunodeficiency syndrome	0.000141	0.00597	CbGpPWpGaD
Fentanyl—OPRK1—Peptide ligand-binding receptors—CXCL12—acquired immunodeficiency syndrome	0.000141	0.00597	CbGpPWpGaD
Fentanyl—OPRM1—Peptide ligand-binding receptors—CCL3—acquired immunodeficiency syndrome	0.00014	0.00594	CbGpPWpGaD
Fentanyl—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.000138	0.00583	CbGpPWpGaD
Fentanyl—OPRK1—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.000137	0.00581	CbGpPWpGaD
Fentanyl—CYP3A4—nervous system—acquired immunodeficiency syndrome	0.000136	0.0136	CbGeAlD
Fentanyl—OPRD1—G alpha (i) signalling events—CXCL12—acquired immunodeficiency syndrome	0.000136	0.00575	CbGpPWpGaD
Fentanyl—OPRD1—G alpha (i) signalling events—CXCR4—acquired immunodeficiency syndrome	0.000136	0.00575	CbGpPWpGaD
Fentanyl—OPRD1—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.000134	0.00567	CbGpPWpGaD
Fentanyl—OPRD1—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.000133	0.00561	CbGpPWpGaD
Fentanyl—CYP3A4—central nervous system—acquired immunodeficiency syndrome	0.000131	0.0131	CbGeAlD
Fentanyl—ABCB1—HIF-1-alpha transcription factor network—CXCR4—acquired immunodeficiency syndrome	0.00013	0.00552	CbGpPWpGaD
Fentanyl—ABCB1—HIF-1-alpha transcription factor network—CXCL12—acquired immunodeficiency syndrome	0.00013	0.00552	CbGpPWpGaD
Fentanyl—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.000127	0.00537	CbGpPWpGaD
Fentanyl—OPRM1—Peptide ligand-binding receptors—CCR2—acquired immunodeficiency syndrome	0.000127	0.00537	CbGpPWpGaD
Fentanyl—OPRK1—G alpha (i) signalling events—CCR2—acquired immunodeficiency syndrome	0.000127	0.00536	CbGpPWpGaD
Fentanyl—OPRD1—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.000126	0.00533	CbGpPWpGaD
Fentanyl—ABCB1—lymphoid tissue—acquired immunodeficiency syndrome	0.000126	0.0126	CbGeAlD
Fentanyl—ABCB1—digestive system—acquired immunodeficiency syndrome	0.000124	0.0124	CbGeAlD
Fentanyl—OPRK1—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.000124	0.00525	CbGpPWpGaD
Fentanyl—OPRD1—Peptide ligand-binding receptors—CCL5—acquired immunodeficiency syndrome	0.000123	0.00518	CbGpPWpGaD
Fentanyl—OPRM1—Peptide ligand-binding receptors—CXCL12—acquired immunodeficiency syndrome	0.000119	0.00505	CbGpPWpGaD
Fentanyl—OPRM1—Peptide ligand-binding receptors—CXCR4—acquired immunodeficiency syndrome	0.000119	0.00505	CbGpPWpGaD
Fentanyl—OPRK1—G alpha (i) signalling events—CXCR4—acquired immunodeficiency syndrome	0.000119	0.00504	CbGpPWpGaD
Fentanyl—OPRK1—G alpha (i) signalling events—CXCL12—acquired immunodeficiency syndrome	0.000119	0.00504	CbGpPWpGaD
Fentanyl—ABCB1—blood—acquired immunodeficiency syndrome	0.000119	0.0119	CbGeAlD
Fentanyl—OPRK1—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.000118	0.00497	CbGpPWpGaD
Fentanyl—OPRK1—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.000116	0.00492	CbGpPWpGaD
Fentanyl—OPRM1—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.000116	0.00491	CbGpPWpGaD
Fentanyl—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.000115	0.00486	CbGpPWpGaD
Fentanyl—ABCB1—bone marrow—acquired immunodeficiency syndrome	0.000115	0.0115	CbGeAlD
Fentanyl—ABCB1—spinal cord—acquired immunodeficiency syndrome	0.000114	0.0114	CbGeAlD
Fentanyl—ABCB1—Allograft Rejection—CXCL12—acquired immunodeficiency syndrome	0.000113	0.00478	CbGpPWpGaD
Fentanyl—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.000111	0.00471	CbGpPWpGaD
Fentanyl—OPRK1—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.000111	0.00468	CbGpPWpGaD
Fentanyl—OPRD1—Peptide ligand-binding receptors—CCR5—acquired immunodeficiency syndrome	0.00011	0.00467	CbGpPWpGaD
Fentanyl—ABCB1—vagina—acquired immunodeficiency syndrome	0.00011	0.011	CbGeAlD
Fentanyl—OPRD1—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.000108	0.00457	CbGpPWpGaD
Fentanyl—OPRD1—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.000108	0.00457	CbGpPWpGaD
Fentanyl—OPRK1—Peptide ligand-binding receptors—CCL5—acquired immunodeficiency syndrome	0.000107	0.00454	CbGpPWpGaD
Fentanyl—OPRM1—G alpha (i) signalling events—CCR2—acquired immunodeficiency syndrome	0.000107	0.00453	CbGpPWpGaD
Fentanyl—OPRM1—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.000105	0.00444	CbGpPWpGaD
Fentanyl—ABCB1—lung—acquired immunodeficiency syndrome	0.000104	0.0104	CbGeAlD
Fentanyl—OPRD1—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	0.000103	0.00437	CbGpPWpGaD
Fentanyl—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.000101	0.00426	CbGpPWpGaD
Fentanyl—OPRM1—G alpha (i) signalling events—CXCL12—acquired immunodeficiency syndrome	0.000101	0.00426	CbGpPWpGaD
Fentanyl—OPRM1—G alpha (i) signalling events—CXCR4—acquired immunodeficiency syndrome	0.000101	0.00426	CbGpPWpGaD
Fentanyl—OPRM1—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	9.94e-05	0.0042	CbGpPWpGaD
Fentanyl—OPRM1—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	9.83e-05	0.00416	CbGpPWpGaD
Fentanyl—OPRK1—Peptide ligand-binding receptors—CCR5—acquired immunodeficiency syndrome	9.68e-05	0.00409	CbGpPWpGaD
Fentanyl—OPRD1—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	9.67e-05	0.00409	CbGpPWpGaD
Fentanyl—ABCB1—nervous system—acquired immunodeficiency syndrome	9.62e-05	0.00963	CbGeAlD
Fentanyl—OPRK1—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	9.47e-05	0.00401	CbGpPWpGaD
Fentanyl—OPRK1—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	9.47e-05	0.00401	CbGpPWpGaD
Fentanyl—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	9.41e-05	0.00398	CbGpPWpGaD
Fentanyl—OPRM1—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	9.34e-05	0.00395	CbGpPWpGaD
Fentanyl—OPRM1—TCR Signaling Pathway—CD4—acquired immunodeficiency syndrome	9.34e-05	0.00395	CbGpPWpGaD
Fentanyl—OPRD1—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	9.31e-05	0.00394	CbGpPWpGaD
Fentanyl—ABCB1—central nervous system—acquired immunodeficiency syndrome	9.27e-05	0.00927	CbGeAlD
Fentanyl—OPRM1—Peptide ligand-binding receptors—CCL5—acquired immunodeficiency syndrome	9.08e-05	0.00384	CbGpPWpGaD
Fentanyl—OPRK1—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	9.06e-05	0.00383	CbGpPWpGaD
Fentanyl—OPRD1—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	8.75e-05	0.0037	CbGpPWpGaD
Fentanyl—OPRD1—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	8.64e-05	0.00366	CbGpPWpGaD
Fentanyl—ABCB1—Allograft Rejection—IL10—acquired immunodeficiency syndrome	8.56e-05	0.00362	CbGpPWpGaD
Fentanyl—ABCB1—Allograft Rejection—CD40LG—acquired immunodeficiency syndrome	8.56e-05	0.00362	CbGpPWpGaD
Fentanyl—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	8.51e-05	0.0036	CbGpPWpGaD
Fentanyl—OPRK1—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	8.48e-05	0.00359	CbGpPWpGaD
Fentanyl—ABCB1—Allograft Rejection—IL4—acquired immunodeficiency syndrome	8.33e-05	0.00352	CbGpPWpGaD
Fentanyl—OPRD1—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	8.23e-05	0.00348	CbGpPWpGaD
Fentanyl—OPRD1—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	8.23e-05	0.00348	CbGpPWpGaD
Fentanyl—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	8.22e-05	0.00348	CbGpPWpGaD
Fentanyl—OPRM1—Peptide ligand-binding receptors—CCR5—acquired immunodeficiency syndrome	8.18e-05	0.00346	CbGpPWpGaD
Fentanyl—OPRK1—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	8.16e-05	0.00345	CbGpPWpGaD
Fentanyl—ABCB1—Allograft Rejection—HLA-B—acquired immunodeficiency syndrome	8.14e-05	0.00344	CbGpPWpGaD
Fentanyl—OPRD1—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	8.04e-05	0.0034	CbGpPWpGaD
Fentanyl—OPRM1—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	8.01e-05	0.00339	CbGpPWpGaD
Fentanyl—OPRM1—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	8.01e-05	0.00339	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	7.84e-05	0.00331	CbGpPWpGaD
Fentanyl—OPRK1—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	7.67e-05	0.00324	CbGpPWpGaD
Fentanyl—OPRM1—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	7.66e-05	0.00324	CbGpPWpGaD
Fentanyl—OPRK1—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	7.58e-05	0.00321	CbGpPWpGaD
Fentanyl—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	7.4e-05	0.00313	CbGpPWpGaD
Fentanyl—ABCB1—brain—acquired immunodeficiency syndrome	7.36e-05	0.00736	CbGeAlD
Fentanyl—Loss of consciousness—Saquinavir—acquired immunodeficiency syndrome	7.34e-05	0.000286	CcSEcCtD
Fentanyl—Unspecified disorder of skin and subcutaneous tissue—Ritonavir—acquired immunodeficiency syndrome	7.33e-05	0.000286	CcSEcCtD
Fentanyl—Gastrointestinal disorder—Indinavir—acquired immunodeficiency syndrome	7.31e-05	0.000285	CcSEcCtD
Fentanyl—Pruritus—Abacavir—acquired immunodeficiency syndrome	7.3e-05	0.000284	CcSEcCtD
Fentanyl—Fatigue—Indinavir—acquired immunodeficiency syndrome	7.3e-05	0.000284	CcSEcCtD
Fentanyl—Anorexia—Delavirdine—acquired immunodeficiency syndrome	7.3e-05	0.000284	CcSEcCtD
Fentanyl—Discomfort—Ritonavir—acquired immunodeficiency syndrome	7.3e-05	0.000284	CcSEcCtD
Fentanyl—Musculoskeletal discomfort—Efavirenz—acquired immunodeficiency syndrome	7.29e-05	0.000284	CcSEcCtD
Fentanyl—Cough—Saquinavir—acquired immunodeficiency syndrome	7.28e-05	0.000284	CcSEcCtD
Fentanyl—OPRD1—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	7.27e-05	0.00307	CbGpPWpGaD
Fentanyl—Pain—Indinavir—acquired immunodeficiency syndrome	7.24e-05	0.000282	CcSEcCtD
Fentanyl—Constipation—Indinavir—acquired immunodeficiency syndrome	7.24e-05	0.000282	CcSEcCtD
Fentanyl—Insomnia—Efavirenz—acquired immunodeficiency syndrome	7.24e-05	0.000282	CcSEcCtD
Fentanyl—Urticaria—Zidovudine—acquired immunodeficiency syndrome	7.23e-05	0.000282	CcSEcCtD
Fentanyl—Convulsion—Saquinavir—acquired immunodeficiency syndrome	7.23e-05	0.000282	CcSEcCtD
Fentanyl—Dry mouth—Ritonavir—acquired immunodeficiency syndrome	7.22e-05	0.000281	CcSEcCtD
Fentanyl—OPRK1—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	7.21e-05	0.00305	CbGpPWpGaD
Fentanyl—OPRK1—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	7.21e-05	0.00305	CbGpPWpGaD
Fentanyl—Hypertension—Saquinavir—acquired immunodeficiency syndrome	7.21e-05	0.000281	CcSEcCtD
Fentanyl—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	7.21e-05	0.00305	CbGpPWpGaD
Fentanyl—Abdominal pain—Zidovudine—acquired immunodeficiency syndrome	7.2e-05	0.00028	CcSEcCtD
Fentanyl—Body temperature increased—Zidovudine—acquired immunodeficiency syndrome	7.2e-05	0.00028	CcSEcCtD
Fentanyl—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	7.19e-05	0.00028	CcSEcCtD
Fentanyl—Paraesthesia—Efavirenz—acquired immunodeficiency syndrome	7.18e-05	0.00028	CcSEcCtD
Fentanyl—Malaise—Lamivudine—acquired immunodeficiency syndrome	7.18e-05	0.00028	CcSEcCtD
Fentanyl—OPRM1—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	7.17e-05	0.00303	CbGpPWpGaD
Fentanyl—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	7.17e-05	0.000279	CcSEcCtD
Fentanyl—Nausea—Didanosine—acquired immunodeficiency syndrome	7.17e-05	0.000279	CcSEcCtD
Fentanyl—Vertigo—Lamivudine—acquired immunodeficiency syndrome	7.15e-05	0.000279	CcSEcCtD
Fentanyl—Hypotension—Delavirdine—acquired immunodeficiency syndrome	7.15e-05	0.000279	CcSEcCtD
Fentanyl—Syncope—Lamivudine—acquired immunodeficiency syndrome	7.14e-05	0.000278	CcSEcCtD
Fentanyl—Confusional state—Ritonavir—acquired immunodeficiency syndrome	7.14e-05	0.000278	CcSEcCtD
Fentanyl—Dyspnoea—Efavirenz—acquired immunodeficiency syndrome	7.13e-05	0.000278	CcSEcCtD
Fentanyl—Leukopenia—Lamivudine—acquired immunodeficiency syndrome	7.13e-05	0.000278	CcSEcCtD
Fentanyl—Somnolence—Efavirenz—acquired immunodeficiency syndrome	7.11e-05	0.000277	CcSEcCtD
Fentanyl—ABCB1—lymph node—acquired immunodeficiency syndrome	7.11e-05	0.00711	CbGeAlD
Fentanyl—Myalgia—Saquinavir—acquired immunodeficiency syndrome	7.11e-05	0.000277	CcSEcCtD
Fentanyl—Chest pain—Saquinavir—acquired immunodeficiency syndrome	7.11e-05	0.000277	CcSEcCtD
Fentanyl—Arthralgia—Saquinavir—acquired immunodeficiency syndrome	7.11e-05	0.000277	CcSEcCtD
Fentanyl—Anxiety—Saquinavir—acquired immunodeficiency syndrome	7.08e-05	0.000276	CcSEcCtD
Fentanyl—Oedema—Ritonavir—acquired immunodeficiency syndrome	7.08e-05	0.000276	CcSEcCtD
Fentanyl—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	7.06e-05	0.000275	CcSEcCtD
Fentanyl—Unspecified disorder of skin and subcutaneous tissue—Saquinavir—acquired immunodeficiency syndrome	7.06e-05	0.000275	CcSEcCtD
Fentanyl—OPRK1—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	7.05e-05	0.00298	CbGpPWpGaD
Fentanyl—Dyspepsia—Efavirenz—acquired immunodeficiency syndrome	7.04e-05	0.000274	CcSEcCtD
Fentanyl—Discomfort—Saquinavir—acquired immunodeficiency syndrome	7.02e-05	0.000274	CcSEcCtD
Fentanyl—Loss of consciousness—Lamivudine—acquired immunodeficiency syndrome	7e-05	0.000273	CcSEcCtD
Fentanyl—Feeling abnormal—Indinavir—acquired immunodeficiency syndrome	6.98e-05	0.000272	CcSEcCtD
Fentanyl—Musculoskeletal discomfort—Delavirdine—acquired immunodeficiency syndrome	6.97e-05	0.000272	CcSEcCtD
Fentanyl—Shock—Ritonavir—acquired immunodeficiency syndrome	6.96e-05	0.000271	CcSEcCtD
Fentanyl—Decreased appetite—Efavirenz—acquired immunodeficiency syndrome	6.95e-05	0.000271	CcSEcCtD
Fentanyl—Dry mouth—Saquinavir—acquired immunodeficiency syndrome	6.95e-05	0.000271	CcSEcCtD
Fentanyl—Cough—Lamivudine—acquired immunodeficiency syndrome	6.95e-05	0.000271	CcSEcCtD
Fentanyl—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	6.95e-05	0.000271	CcSEcCtD
Fentanyl—Nervous system disorder—Ritonavir—acquired immunodeficiency syndrome	6.94e-05	0.00027	CcSEcCtD
Fentanyl—Thrombocytopenia—Ritonavir—acquired immunodeficiency syndrome	6.93e-05	0.00027	CcSEcCtD
Fentanyl—Dizziness—Stavudine—acquired immunodeficiency syndrome	6.93e-05	0.00027	CcSEcCtD
Fentanyl—Gastrointestinal pain—Indinavir—acquired immunodeficiency syndrome	6.92e-05	0.00027	CcSEcCtD
Fentanyl—Insomnia—Delavirdine—acquired immunodeficiency syndrome	6.92e-05	0.00027	CcSEcCtD
Fentanyl—Tachycardia—Ritonavir—acquired immunodeficiency syndrome	6.91e-05	0.000269	CcSEcCtD
Fentanyl—Gastrointestinal disorder—Efavirenz—acquired immunodeficiency syndrome	6.91e-05	0.000269	CcSEcCtD
Fentanyl—OPRM1—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	6.9e-05	0.00292	CbGpPWpGaD
Fentanyl—Convulsion—Lamivudine—acquired immunodeficiency syndrome	6.9e-05	0.000269	CcSEcCtD
Fentanyl—Vomiting—Nevirapine—acquired immunodeficiency syndrome	6.9e-05	0.000269	CcSEcCtD
Fentanyl—Fatigue—Efavirenz—acquired immunodeficiency syndrome	6.9e-05	0.000269	CcSEcCtD
Fentanyl—Skin disorder—Ritonavir—acquired immunodeficiency syndrome	6.88e-05	0.000268	CcSEcCtD
Fentanyl—Paraesthesia—Delavirdine—acquired immunodeficiency syndrome	6.87e-05	0.000268	CcSEcCtD
Fentanyl—OPRK1—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	6.87e-05	0.00291	CbGpPWpGaD
Fentanyl—Confusional state—Saquinavir—acquired immunodeficiency syndrome	6.87e-05	0.000268	CcSEcCtD
Fentanyl—Hyperhidrosis—Ritonavir—acquired immunodeficiency syndrome	6.84e-05	0.000267	CcSEcCtD
Fentanyl—Pain—Efavirenz—acquired immunodeficiency syndrome	6.84e-05	0.000267	CcSEcCtD
Fentanyl—Constipation—Efavirenz—acquired immunodeficiency syndrome	6.84e-05	0.000267	CcSEcCtD
Fentanyl—Rash—Nevirapine—acquired immunodeficiency syndrome	6.84e-05	0.000267	CcSEcCtD
Fentanyl—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	6.83e-05	0.000266	CcSEcCtD
Fentanyl—Dyspnoea—Delavirdine—acquired immunodeficiency syndrome	6.82e-05	0.000266	CcSEcCtD
Fentanyl—Dizziness—Abacavir—acquired immunodeficiency syndrome	6.82e-05	0.000266	CcSEcCtD
Fentanyl—Oedema—Saquinavir—acquired immunodeficiency syndrome	6.81e-05	0.000265	CcSEcCtD
Fentanyl—Somnolence—Delavirdine—acquired immunodeficiency syndrome	6.8e-05	0.000265	CcSEcCtD
Fentanyl—Headache—Nevirapine—acquired immunodeficiency syndrome	6.8e-05	0.000265	CcSEcCtD
Fentanyl—Chest pain—Lamivudine—acquired immunodeficiency syndrome	6.78e-05	0.000264	CcSEcCtD
Fentanyl—Myalgia—Lamivudine—acquired immunodeficiency syndrome	6.78e-05	0.000264	CcSEcCtD
Fentanyl—Arthralgia—Lamivudine—acquired immunodeficiency syndrome	6.78e-05	0.000264	CcSEcCtD
Fentanyl—Infection—Saquinavir—acquired immunodeficiency syndrome	6.77e-05	0.000264	CcSEcCtD
Fentanyl—Anxiety—Lamivudine—acquired immunodeficiency syndrome	6.76e-05	0.000263	CcSEcCtD
Fentanyl—Anorexia—Ritonavir—acquired immunodeficiency syndrome	6.75e-05	0.000263	CcSEcCtD
Fentanyl—Dyspepsia—Delavirdine—acquired immunodeficiency syndrome	6.74e-05	0.000263	CcSEcCtD
Fentanyl—Unspecified disorder of skin and subcutaneous tissue—Lamivudine—acquired immunodeficiency syndrome	6.73e-05	0.000262	CcSEcCtD
Fentanyl—Urticaria—Indinavir—acquired immunodeficiency syndrome	6.73e-05	0.000262	CcSEcCtD
Fentanyl—Shock—Saquinavir—acquired immunodeficiency syndrome	6.7e-05	0.000261	CcSEcCtD
Fentanyl—Discomfort—Lamivudine—acquired immunodeficiency syndrome	6.7e-05	0.000261	CcSEcCtD
Fentanyl—Abdominal pain—Indinavir—acquired immunodeficiency syndrome	6.69e-05	0.000261	CcSEcCtD
Fentanyl—Body temperature increased—Indinavir—acquired immunodeficiency syndrome	6.69e-05	0.000261	CcSEcCtD
Fentanyl—Nervous system disorder—Saquinavir—acquired immunodeficiency syndrome	6.68e-05	0.00026	CcSEcCtD
Fentanyl—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	6.68e-05	0.00026	CcSEcCtD
Fentanyl—Thrombocytopenia—Saquinavir—acquired immunodeficiency syndrome	6.67e-05	0.00026	CcSEcCtD
Fentanyl—Vomiting—Stavudine—acquired immunodeficiency syndrome	6.66e-05	0.000259	CcSEcCtD
Fentanyl—Decreased appetite—Delavirdine—acquired immunodeficiency syndrome	6.65e-05	0.000259	CcSEcCtD
Fentanyl—Dry mouth—Lamivudine—acquired immunodeficiency syndrome	6.63e-05	0.000258	CcSEcCtD
Fentanyl—Rash—Nelfinavir—acquired immunodeficiency syndrome	6.62e-05	0.000258	CcSEcCtD
Fentanyl—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	6.62e-05	0.000258	CcSEcCtD
Fentanyl—Skin disorder—Saquinavir—acquired immunodeficiency syndrome	6.62e-05	0.000258	CcSEcCtD
Fentanyl—Hypotension—Ritonavir—acquired immunodeficiency syndrome	6.61e-05	0.000258	CcSEcCtD
Fentanyl—Gastrointestinal disorder—Delavirdine—acquired immunodeficiency syndrome	6.61e-05	0.000257	CcSEcCtD
Fentanyl—Rash—Stavudine—acquired immunodeficiency syndrome	6.6e-05	0.000257	CcSEcCtD
Fentanyl—Fatigue—Delavirdine—acquired immunodeficiency syndrome	6.6e-05	0.000257	CcSEcCtD
Fentanyl—Dermatitis—Stavudine—acquired immunodeficiency syndrome	6.6e-05	0.000257	CcSEcCtD
Fentanyl—Feeling abnormal—Efavirenz—acquired immunodeficiency syndrome	6.59e-05	0.000257	CcSEcCtD
Fentanyl—Hyperhidrosis—Saquinavir—acquired immunodeficiency syndrome	6.59e-05	0.000257	CcSEcCtD
Fentanyl—Headache—Nelfinavir—acquired immunodeficiency syndrome	6.58e-05	0.000256	CcSEcCtD
Fentanyl—Headache—Stavudine—acquired immunodeficiency syndrome	6.56e-05	0.000256	CcSEcCtD
Fentanyl—Vomiting—Abacavir—acquired immunodeficiency syndrome	6.56e-05	0.000256	CcSEcCtD
Fentanyl—Confusional state—Lamivudine—acquired immunodeficiency syndrome	6.55e-05	0.000255	CcSEcCtD
Fentanyl—Constipation—Delavirdine—acquired immunodeficiency syndrome	6.55e-05	0.000255	CcSEcCtD
Fentanyl—Pain—Delavirdine—acquired immunodeficiency syndrome	6.55e-05	0.000255	CcSEcCtD
Fentanyl—Gastrointestinal pain—Efavirenz—acquired immunodeficiency syndrome	6.54e-05	0.000255	CcSEcCtD
Fentanyl—Asthenia—Zidovudine—acquired immunodeficiency syndrome	6.53e-05	0.000254	CcSEcCtD
Fentanyl—Rash—Abacavir—acquired immunodeficiency syndrome	6.51e-05	0.000253	CcSEcCtD
Fentanyl—Dermatitis—Abacavir—acquired immunodeficiency syndrome	6.5e-05	0.000253	CcSEcCtD
Fentanyl—Anaphylactic shock—Lamivudine—acquired immunodeficiency syndrome	6.5e-05	0.000253	CcSEcCtD
Fentanyl—Oedema—Lamivudine—acquired immunodeficiency syndrome	6.5e-05	0.000253	CcSEcCtD
Fentanyl—Anorexia—Saquinavir—acquired immunodeficiency syndrome	6.49e-05	0.000253	CcSEcCtD
Fentanyl—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	6.49e-05	0.00275	CbGpPWpGaD
Fentanyl—OPRM1—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	6.48e-05	0.00274	CbGpPWpGaD
Fentanyl—Headache—Abacavir—acquired immunodeficiency syndrome	6.46e-05	0.000252	CcSEcCtD
Fentanyl—Infection—Lamivudine—acquired immunodeficiency syndrome	6.46e-05	0.000252	CcSEcCtD
Fentanyl—Musculoskeletal discomfort—Ritonavir—acquired immunodeficiency syndrome	6.45e-05	0.000251	CcSEcCtD
Fentanyl—Nausea—Nevirapine—acquired immunodeficiency syndrome	6.44e-05	0.000251	CcSEcCtD
Fentanyl—Pruritus—Zidovudine—acquired immunodeficiency syndrome	6.44e-05	0.000251	CcSEcCtD
Fentanyl—OPRM1—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	6.4e-05	0.00271	CbGpPWpGaD
Fentanyl—Insomnia—Ritonavir—acquired immunodeficiency syndrome	6.4e-05	0.000249	CcSEcCtD
Fentanyl—Shock—Lamivudine—acquired immunodeficiency syndrome	6.39e-05	0.000249	CcSEcCtD
Fentanyl—Nervous system disorder—Lamivudine—acquired immunodeficiency syndrome	6.37e-05	0.000248	CcSEcCtD
Fentanyl—OPRK1—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	6.37e-05	0.0027	CbGpPWpGaD
Fentanyl—Hypotension—Saquinavir—acquired immunodeficiency syndrome	6.37e-05	0.000248	CcSEcCtD
Fentanyl—Thrombocytopenia—Lamivudine—acquired immunodeficiency syndrome	6.36e-05	0.000248	CcSEcCtD
Fentanyl—Paraesthesia—Ritonavir—acquired immunodeficiency syndrome	6.36e-05	0.000248	CcSEcCtD
Fentanyl—Urticaria—Efavirenz—acquired immunodeficiency syndrome	6.36e-05	0.000248	CcSEcCtD
Fentanyl—Abdominal pain—Efavirenz—acquired immunodeficiency syndrome	6.32e-05	0.000246	CcSEcCtD
Fentanyl—Body temperature increased—Efavirenz—acquired immunodeficiency syndrome	6.32e-05	0.000246	CcSEcCtD
Fentanyl—Skin disorder—Lamivudine—acquired immunodeficiency syndrome	6.31e-05	0.000246	CcSEcCtD
Fentanyl—Dyspnoea—Ritonavir—acquired immunodeficiency syndrome	6.31e-05	0.000246	CcSEcCtD
Fentanyl—Feeling abnormal—Delavirdine—acquired immunodeficiency syndrome	6.31e-05	0.000246	CcSEcCtD
Fentanyl—Somnolence—Ritonavir—acquired immunodeficiency syndrome	6.29e-05	0.000245	CcSEcCtD
Fentanyl—Hyperhidrosis—Lamivudine—acquired immunodeficiency syndrome	6.28e-05	0.000245	CcSEcCtD
Fentanyl—Gastrointestinal pain—Delavirdine—acquired immunodeficiency syndrome	6.26e-05	0.000244	CcSEcCtD
Fentanyl—OPRD1—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	6.26e-05	0.00265	CbGpPWpGaD
Fentanyl—Nausea—Nelfinavir—acquired immunodeficiency syndrome	6.24e-05	0.000243	CcSEcCtD
Fentanyl—Hypersensitivity—Indinavir—acquired immunodeficiency syndrome	6.24e-05	0.000243	CcSEcCtD
Fentanyl—Dyspepsia—Ritonavir—acquired immunodeficiency syndrome	6.23e-05	0.000243	CcSEcCtD
Fentanyl—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	6.23e-05	0.000243	CcSEcCtD
Fentanyl—Nausea—Stavudine—acquired immunodeficiency syndrome	6.22e-05	0.000242	CcSEcCtD
Fentanyl—Musculoskeletal discomfort—Saquinavir—acquired immunodeficiency syndrome	6.21e-05	0.000242	CcSEcCtD
Fentanyl—Anorexia—Lamivudine—acquired immunodeficiency syndrome	6.2e-05	0.000241	CcSEcCtD
Fentanyl—Insomnia—Saquinavir—acquired immunodeficiency syndrome	6.16e-05	0.00024	CcSEcCtD
Fentanyl—Decreased appetite—Ritonavir—acquired immunodeficiency syndrome	6.15e-05	0.00024	CcSEcCtD
Fentanyl—Nausea—Abacavir—acquired immunodeficiency syndrome	6.13e-05	0.000239	CcSEcCtD
Fentanyl—Paraesthesia—Saquinavir—acquired immunodeficiency syndrome	6.12e-05	0.000238	CcSEcCtD
Fentanyl—Gastrointestinal disorder—Ritonavir—acquired immunodeficiency syndrome	6.11e-05	0.000238	CcSEcCtD
Fentanyl—Fatigue—Ritonavir—acquired immunodeficiency syndrome	6.1e-05	0.000238	CcSEcCtD
Fentanyl—OPRM1—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	6.1e-05	0.00258	CbGpPWpGaD
Fentanyl—OPRM1—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	6.1e-05	0.00258	CbGpPWpGaD
Fentanyl—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	6.09e-05	0.00258	CbGpPWpGaD
Fentanyl—Urticaria—Delavirdine—acquired immunodeficiency syndrome	6.08e-05	0.000237	CcSEcCtD
Fentanyl—Asthenia—Indinavir—acquired immunodeficiency syndrome	6.07e-05	0.000237	CcSEcCtD
Fentanyl—Dyspnoea—Saquinavir—acquired immunodeficiency syndrome	6.07e-05	0.000237	CcSEcCtD
Fentanyl—Hypotension—Lamivudine—acquired immunodeficiency syndrome	6.07e-05	0.000237	CcSEcCtD
Fentanyl—Somnolence—Saquinavir—acquired immunodeficiency syndrome	6.06e-05	0.000236	CcSEcCtD
Fentanyl—Pain—Ritonavir—acquired immunodeficiency syndrome	6.05e-05	0.000236	CcSEcCtD
Fentanyl—Constipation—Ritonavir—acquired immunodeficiency syndrome	6.05e-05	0.000236	CcSEcCtD
Fentanyl—Body temperature increased—Delavirdine—acquired immunodeficiency syndrome	6.05e-05	0.000236	CcSEcCtD
Fentanyl—Abdominal pain—Delavirdine—acquired immunodeficiency syndrome	6.05e-05	0.000236	CcSEcCtD
Fentanyl—Dizziness—Zidovudine—acquired immunodeficiency syndrome	6.02e-05	0.000235	CcSEcCtD
Fentanyl—Dyspepsia—Saquinavir—acquired immunodeficiency syndrome	6e-05	0.000234	CcSEcCtD
Fentanyl—Pruritus—Indinavir—acquired immunodeficiency syndrome	5.99e-05	0.000233	CcSEcCtD
Fentanyl—OPRM1—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	5.96e-05	0.00252	CbGpPWpGaD
Fentanyl—Decreased appetite—Saquinavir—acquired immunodeficiency syndrome	5.92e-05	0.000231	CcSEcCtD
Fentanyl—Musculoskeletal discomfort—Lamivudine—acquired immunodeficiency syndrome	5.92e-05	0.000231	CcSEcCtD
Fentanyl—Hypersensitivity—Efavirenz—acquired immunodeficiency syndrome	5.89e-05	0.00023	CcSEcCtD
Fentanyl—Gastrointestinal disorder—Saquinavir—acquired immunodeficiency syndrome	5.88e-05	0.000229	CcSEcCtD
Fentanyl—Insomnia—Lamivudine—acquired immunodeficiency syndrome	5.88e-05	0.000229	CcSEcCtD
Fentanyl—Fatigue—Saquinavir—acquired immunodeficiency syndrome	5.87e-05	0.000229	CcSEcCtD
Fentanyl—Paraesthesia—Lamivudine—acquired immunodeficiency syndrome	5.84e-05	0.000227	CcSEcCtD
Fentanyl—Feeling abnormal—Ritonavir—acquired immunodeficiency syndrome	5.83e-05	0.000227	CcSEcCtD
Fentanyl—Constipation—Saquinavir—acquired immunodeficiency syndrome	5.83e-05	0.000227	CcSEcCtD
Fentanyl—Pain—Saquinavir—acquired immunodeficiency syndrome	5.83e-05	0.000227	CcSEcCtD
Fentanyl—OPRM1—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	5.81e-05	0.00246	CbGpPWpGaD
Fentanyl—Dyspnoea—Lamivudine—acquired immunodeficiency syndrome	5.79e-05	0.000226	CcSEcCtD
Fentanyl—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	5.79e-05	0.000226	CcSEcCtD
Fentanyl—Vomiting—Zidovudine—acquired immunodeficiency syndrome	5.79e-05	0.000226	CcSEcCtD
Fentanyl—Gastrointestinal pain—Ritonavir—acquired immunodeficiency syndrome	5.79e-05	0.000226	CcSEcCtD
Fentanyl—Somnolence—Lamivudine—acquired immunodeficiency syndrome	5.78e-05	0.000225	CcSEcCtD
Fentanyl—Rash—Zidovudine—acquired immunodeficiency syndrome	5.74e-05	0.000224	CcSEcCtD
Fentanyl—Asthenia—Efavirenz—acquired immunodeficiency syndrome	5.74e-05	0.000224	CcSEcCtD
Fentanyl—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	5.74e-05	0.000223	CcSEcCtD
Fentanyl—Dyspepsia—Lamivudine—acquired immunodeficiency syndrome	5.72e-05	0.000223	CcSEcCtD
Fentanyl—Headache—Zidovudine—acquired immunodeficiency syndrome	5.7e-05	0.000222	CcSEcCtD
Fentanyl—Pruritus—Efavirenz—acquired immunodeficiency syndrome	5.66e-05	0.000221	CcSEcCtD
Fentanyl—Decreased appetite—Lamivudine—acquired immunodeficiency syndrome	5.65e-05	0.00022	CcSEcCtD
Fentanyl—Hypersensitivity—Delavirdine—acquired immunodeficiency syndrome	5.64e-05	0.00022	CcSEcCtD
Fentanyl—OPRD1—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	5.64e-05	0.00238	CbGpPWpGaD
Fentanyl—Urticaria—Ritonavir—acquired immunodeficiency syndrome	5.62e-05	0.000219	CcSEcCtD
Fentanyl—Feeling abnormal—Saquinavir—acquired immunodeficiency syndrome	5.61e-05	0.000219	CcSEcCtD
Fentanyl—Gastrointestinal disorder—Lamivudine—acquired immunodeficiency syndrome	5.61e-05	0.000219	CcSEcCtD
Fentanyl—Fatigue—Lamivudine—acquired immunodeficiency syndrome	5.6e-05	0.000218	CcSEcCtD
Fentanyl—Dizziness—Indinavir—acquired immunodeficiency syndrome	5.6e-05	0.000218	CcSEcCtD
Fentanyl—Abdominal pain—Ritonavir—acquired immunodeficiency syndrome	5.6e-05	0.000218	CcSEcCtD
Fentanyl—Body temperature increased—Ritonavir—acquired immunodeficiency syndrome	5.6e-05	0.000218	CcSEcCtD
Fentanyl—Gastrointestinal pain—Saquinavir—acquired immunodeficiency syndrome	5.57e-05	0.000217	CcSEcCtD
Fentanyl—Pain—Lamivudine—acquired immunodeficiency syndrome	5.56e-05	0.000217	CcSEcCtD
Fentanyl—Constipation—Lamivudine—acquired immunodeficiency syndrome	5.56e-05	0.000217	CcSEcCtD
Fentanyl—Asthenia—Delavirdine—acquired immunodeficiency syndrome	5.49e-05	0.000214	CcSEcCtD
Fentanyl—OPRK1—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	5.49e-05	0.00232	CbGpPWpGaD
Fentanyl—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	5.49e-05	0.00232	CbGpPWpGaD
Fentanyl—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	5.47e-05	0.000213	CcSEcCtD
Fentanyl—Pruritus—Delavirdine—acquired immunodeficiency syndrome	5.42e-05	0.000211	CcSEcCtD
Fentanyl—Urticaria—Saquinavir—acquired immunodeficiency syndrome	5.41e-05	0.000211	CcSEcCtD
Fentanyl—Nausea—Zidovudine—acquired immunodeficiency syndrome	5.41e-05	0.000211	CcSEcCtD
Fentanyl—OPRM1—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	5.39e-05	0.00228	CbGpPWpGaD
Fentanyl—Body temperature increased—Saquinavir—acquired immunodeficiency syndrome	5.39e-05	0.00021	CcSEcCtD
Fentanyl—Abdominal pain—Saquinavir—acquired immunodeficiency syndrome	5.39e-05	0.00021	CcSEcCtD
Fentanyl—Vomiting—Indinavir—acquired immunodeficiency syndrome	5.38e-05	0.00021	CcSEcCtD
Fentanyl—Feeling abnormal—Lamivudine—acquired immunodeficiency syndrome	5.36e-05	0.000209	CcSEcCtD
Fentanyl—Rash—Indinavir—acquired immunodeficiency syndrome	5.34e-05	0.000208	CcSEcCtD
Fentanyl—Dermatitis—Indinavir—acquired immunodeficiency syndrome	5.33e-05	0.000208	CcSEcCtD
Fentanyl—CYP3A7—Metabolism—TAT—acquired immunodeficiency syndrome	5.32e-05	0.00225	CbGpPWpGaD
Fentanyl—Gastrointestinal pain—Lamivudine—acquired immunodeficiency syndrome	5.31e-05	0.000207	CcSEcCtD
Fentanyl—Headache—Indinavir—acquired immunodeficiency syndrome	5.3e-05	0.000207	CcSEcCtD
Fentanyl—Dizziness—Efavirenz—acquired immunodeficiency syndrome	5.29e-05	0.000206	CcSEcCtD
Fentanyl—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	5.24e-05	0.000204	CcSEcCtD
Fentanyl—Hypersensitivity—Ritonavir—acquired immunodeficiency syndrome	5.21e-05	0.000203	CcSEcCtD
Fentanyl—Urticaria—Lamivudine—acquired immunodeficiency syndrome	5.16e-05	0.000201	CcSEcCtD
Fentanyl—Abdominal pain—Lamivudine—acquired immunodeficiency syndrome	5.14e-05	0.0002	CcSEcCtD
Fentanyl—Body temperature increased—Lamivudine—acquired immunodeficiency syndrome	5.14e-05	0.0002	CcSEcCtD
Fentanyl—Vomiting—Efavirenz—acquired immunodeficiency syndrome	5.09e-05	0.000198	CcSEcCtD
Fentanyl—Asthenia—Ritonavir—acquired immunodeficiency syndrome	5.08e-05	0.000198	CcSEcCtD
Fentanyl—Dizziness—Delavirdine—acquired immunodeficiency syndrome	5.06e-05	0.000197	CcSEcCtD
Fentanyl—OPRM1—TCR Signaling Pathway—IL6—acquired immunodeficiency syndrome	5.05e-05	0.00214	CbGpPWpGaD
Fentanyl—Rash—Efavirenz—acquired immunodeficiency syndrome	5.04e-05	0.000197	CcSEcCtD
Fentanyl—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	5.04e-05	0.000196	CcSEcCtD
Fentanyl—ABCB1—Allograft Rejection—IFNG—acquired immunodeficiency syndrome	5.03e-05	0.00213	CbGpPWpGaD
Fentanyl—Nausea—Indinavir—acquired immunodeficiency syndrome	5.03e-05	0.000196	CcSEcCtD
Fentanyl—Hypersensitivity—Saquinavir—acquired immunodeficiency syndrome	5.02e-05	0.000196	CcSEcCtD
Fentanyl—Headache—Efavirenz—acquired immunodeficiency syndrome	5.01e-05	0.000195	CcSEcCtD
Fentanyl—Pruritus—Ritonavir—acquired immunodeficiency syndrome	5.01e-05	0.000195	CcSEcCtD
Fentanyl—OPRD1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	4.96e-05	0.0021	CbGpPWpGaD
Fentanyl—OPRD1—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	4.94e-05	0.00209	CbGpPWpGaD
Fentanyl—OPRK1—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	4.94e-05	0.00209	CbGpPWpGaD
Fentanyl—Asthenia—Saquinavir—acquired immunodeficiency syndrome	4.89e-05	0.00019	CcSEcCtD
Fentanyl—Vomiting—Delavirdine—acquired immunodeficiency syndrome	4.87e-05	0.00019	CcSEcCtD
Fentanyl—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	4.84e-05	0.000189	CcSEcCtD
Fentanyl—Rash—Delavirdine—acquired immunodeficiency syndrome	4.83e-05	0.000188	CcSEcCtD
Fentanyl—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	4.82e-05	0.000188	CcSEcCtD
Fentanyl—Pruritus—Saquinavir—acquired immunodeficiency syndrome	4.82e-05	0.000188	CcSEcCtD
Fentanyl—Headache—Delavirdine—acquired immunodeficiency syndrome	4.8e-05	0.000187	CcSEcCtD
Fentanyl—Hypersensitivity—Lamivudine—acquired immunodeficiency syndrome	4.79e-05	0.000187	CcSEcCtD
Fentanyl—Nausea—Efavirenz—acquired immunodeficiency syndrome	4.75e-05	0.000185	CcSEcCtD
Fentanyl—OPRD1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	4.75e-05	0.00201	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	4.75e-05	0.00201	CbGpPWpGaD
Fentanyl—Dizziness—Ritonavir—acquired immunodeficiency syndrome	4.68e-05	0.000182	CcSEcCtD
Fentanyl—Asthenia—Lamivudine—acquired immunodeficiency syndrome	4.66e-05	0.000182	CcSEcCtD
Fentanyl—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	4.66e-05	0.000182	CcSEcCtD
Fentanyl—OPRD1—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	4.65e-05	0.00197	CbGpPWpGaD
Fentanyl—OPRD1—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	4.65e-05	0.00197	CbGpPWpGaD
Fentanyl—OPRM1—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	4.64e-05	0.00196	CbGpPWpGaD
Fentanyl—Pruritus—Lamivudine—acquired immunodeficiency syndrome	4.6e-05	0.000179	CcSEcCtD
Fentanyl—Nausea—Delavirdine—acquired immunodeficiency syndrome	4.55e-05	0.000177	CcSEcCtD
Fentanyl—CYP3A7—Metabolism—AGPS—acquired immunodeficiency syndrome	4.53e-05	0.00191	CbGpPWpGaD
Fentanyl—Dizziness—Saquinavir—acquired immunodeficiency syndrome	4.51e-05	0.000176	CcSEcCtD
Fentanyl—Vomiting—Ritonavir—acquired immunodeficiency syndrome	4.5e-05	0.000175	CcSEcCtD
Fentanyl—OPRD1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	4.49e-05	0.0019	CbGpPWpGaD
Fentanyl—ABCB1—Allograft Rejection—IL2—acquired immunodeficiency syndrome	4.47e-05	0.00189	CbGpPWpGaD
Fentanyl—Rash—Ritonavir—acquired immunodeficiency syndrome	4.46e-05	0.000174	CcSEcCtD
Fentanyl—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	4.46e-05	0.000174	CcSEcCtD
Fentanyl—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	4.45e-05	0.000173	CcSEcCtD
Fentanyl—Headache—Ritonavir—acquired immunodeficiency syndrome	4.43e-05	0.000173	CcSEcCtD
Fentanyl—OPRK1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	4.35e-05	0.00184	CbGpPWpGaD
Fentanyl—OPRK1—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	4.34e-05	0.00183	CbGpPWpGaD
Fentanyl—Vomiting—Saquinavir—acquired immunodeficiency syndrome	4.33e-05	0.000169	CcSEcCtD
Fentanyl—Dizziness—Lamivudine—acquired immunodeficiency syndrome	4.3e-05	0.000167	CcSEcCtD
Fentanyl—Rash—Saquinavir—acquired immunodeficiency syndrome	4.3e-05	0.000167	CcSEcCtD
Fentanyl—OPRD1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	4.29e-05	0.00182	CbGpPWpGaD
Fentanyl—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	4.29e-05	0.000167	CcSEcCtD
Fentanyl—Headache—Saquinavir—acquired immunodeficiency syndrome	4.27e-05	0.000166	CcSEcCtD
Fentanyl—OPRD1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	4.22e-05	0.00179	CbGpPWpGaD
Fentanyl—OPRD1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	4.22e-05	0.00179	CbGpPWpGaD
Fentanyl—Nausea—Ritonavir—acquired immunodeficiency syndrome	4.2e-05	0.000164	CcSEcCtD
Fentanyl—OPRM1—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	4.18e-05	0.00177	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	4.16e-05	0.00176	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	4.16e-05	0.00176	CbGpPWpGaD
Fentanyl—Vomiting—Lamivudine—acquired immunodeficiency syndrome	4.13e-05	0.000161	CcSEcCtD
Fentanyl—Rash—Lamivudine—acquired immunodeficiency syndrome	4.1e-05	0.00016	CcSEcCtD
Fentanyl—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	4.09e-05	0.00016	CcSEcCtD
Fentanyl—OPRK1—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	4.08e-05	0.00172	CbGpPWpGaD
Fentanyl—OPRK1—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	4.08e-05	0.00172	CbGpPWpGaD
Fentanyl—Headache—Lamivudine—acquired immunodeficiency syndrome	4.07e-05	0.000159	CcSEcCtD
Fentanyl—Nausea—Saquinavir—acquired immunodeficiency syndrome	4.05e-05	0.000158	CcSEcCtD
Fentanyl—OPRK1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	3.94e-05	0.00167	CbGpPWpGaD
Fentanyl—Nausea—Lamivudine—acquired immunodeficiency syndrome	3.86e-05	0.00015	CcSEcCtD
Fentanyl—CYP3A5—Metabolism—TAT—acquired immunodeficiency syndrome	3.85e-05	0.00163	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	3.76e-05	0.00159	CbGpPWpGaD
Fentanyl—OPRK1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	3.7e-05	0.00157	CbGpPWpGaD
Fentanyl—OPRK1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	3.7e-05	0.00157	CbGpPWpGaD
Fentanyl—OPRM1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	3.68e-05	0.00156	CbGpPWpGaD
Fentanyl—OPRM1—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	3.66e-05	0.00155	CbGpPWpGaD
Fentanyl—OPRD1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	3.54e-05	0.0015	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	3.52e-05	0.00149	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	3.52e-05	0.00149	CbGpPWpGaD
Fentanyl—OPRD1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	3.48e-05	0.00147	CbGpPWpGaD
Fentanyl—OPRM1—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	3.44e-05	0.00146	CbGpPWpGaD
Fentanyl—OPRM1—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	3.44e-05	0.00146	CbGpPWpGaD
Fentanyl—OPRM1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	3.33e-05	0.00141	CbGpPWpGaD
Fentanyl—CYP3A5—Metabolism—AGPS—acquired immunodeficiency syndrome	3.27e-05	0.00138	CbGpPWpGaD
Fentanyl—ABCB1—Allograft Rejection—TNF—acquired immunodeficiency syndrome	3.26e-05	0.00138	CbGpPWpGaD
Fentanyl—OPRD1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	3.21e-05	0.00136	CbGpPWpGaD
Fentanyl—OPRD1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	3.19e-05	0.00135	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	3.18e-05	0.00135	CbGpPWpGaD
Fentanyl—OPRD1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	3.16e-05	0.00134	CbGpPWpGaD
Fentanyl—OPRM1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	3.13e-05	0.00132	CbGpPWpGaD
Fentanyl—OPRM1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	3.13e-05	0.00132	CbGpPWpGaD
Fentanyl—OPRK1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	3.1e-05	0.00131	CbGpPWpGaD
Fentanyl—OPRK1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	3.05e-05	0.00129	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	2.93e-05	0.00124	CbGpPWpGaD
Fentanyl—ABCB1—Metabolism—TAT—acquired immunodeficiency syndrome	2.9e-05	0.00123	CbGpPWpGaD
Fentanyl—OPRD1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	2.89e-05	0.00122	CbGpPWpGaD
Fentanyl—OPRK1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	2.82e-05	0.00119	CbGpPWpGaD
Fentanyl—OPRK1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	2.79e-05	0.00118	CbGpPWpGaD
Fentanyl—OPRK1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	2.77e-05	0.00117	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.65e-05	0.00112	CbGpPWpGaD
Fentanyl—OPRM1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	2.62e-05	0.00111	CbGpPWpGaD
Fentanyl—OPRM1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	2.58e-05	0.00109	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	2.57e-05	0.00109	CbGpPWpGaD
Fentanyl—OPRK1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	2.54e-05	0.00107	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.49e-05	0.00105	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.49e-05	0.00105	CbGpPWpGaD
Fentanyl—ABCB1—Metabolism—AGPS—acquired immunodeficiency syndrome	2.47e-05	0.00104	CbGpPWpGaD
Fentanyl—OPRM1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	2.38e-05	0.00101	CbGpPWpGaD
Fentanyl—OPRM1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	2.36e-05	0.000999	CbGpPWpGaD
Fentanyl—OPRM1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	2.34e-05	0.000992	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.33e-05	0.000984	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.19e-05	0.000925	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.19e-05	0.000925	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	2.17e-05	0.000919	CbGpPWpGaD
Fentanyl—OPRM1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	2.14e-05	0.000907	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.97e-05	0.000831	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.9e-05	0.000802	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.87e-05	0.00079	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.85e-05	0.000782	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.85e-05	0.000782	CbGpPWpGaD
Fentanyl—OPRD1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.84e-05	0.000779	CbGpPWpGaD
Fentanyl—CYP3A4—Metabolism—TAT—acquired immunodeficiency syndrome	1.79e-05	0.000757	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.71e-05	0.000723	CbGpPWpGaD
Fentanyl—OPRD1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.67e-05	0.000707	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.66e-05	0.000704	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.64e-05	0.000693	CbGpPWpGaD
Fentanyl—OPRK1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.61e-05	0.000683	CbGpPWpGaD
Fentanyl—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—acquired immunodeficiency syndrome	1.61e-05	0.00068	CbGpPWpGaD
Fentanyl—CYP3A4—Metabolism—AGPS—acquired immunodeficiency syndrome	1.52e-05	0.000643	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.5e-05	0.000634	CbGpPWpGaD
Fentanyl—OPRK1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.47e-05	0.00062	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.41e-05	0.000595	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.38e-05	0.000586	CbGpPWpGaD
Fentanyl—OPRM1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.36e-05	0.000577	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.27e-05	0.000536	CbGpPWpGaD
Fentanyl—OPRM1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.24e-05	0.000524	CbGpPWpGaD
Fentanyl—ABCB1—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	1.08e-05	0.000457	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	9.88e-06	0.000418	CbGpPWpGaD
Fentanyl—OPRD1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	9.83e-06	0.000416	CbGpPWpGaD
Fentanyl—CYP3A7—Metabolism—ALB—acquired immunodeficiency syndrome	9.28e-06	0.000393	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	8.66e-06	0.000366	CbGpPWpGaD
Fentanyl—OPRK1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	8.62e-06	0.000364	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	7.32e-06	0.00031	CbGpPWpGaD
Fentanyl—OPRM1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	7.28e-06	0.000308	CbGpPWpGaD
Fentanyl—CYP3A5—Metabolism—ALB—acquired immunodeficiency syndrome	6.71e-06	0.000284	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	5.8e-06	0.000246	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	5.09e-06	0.000215	CbGpPWpGaD
Fentanyl—ABCB1—Metabolism—ALB—acquired immunodeficiency syndrome	5.06e-06	0.000214	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	4.3e-06	0.000182	CbGpPWpGaD
Fentanyl—CYP3A4—Metabolism—ALB—acquired immunodeficiency syndrome	3.12e-06	0.000132	CbGpPWpGaD
